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Abstract
The Notch signaling pathway is essential for normal development due to its role in control of cell differentiation,
proliferation and survival. It is also critically involved in tumorigenesis and cancer progression. A key enzyme in the
activation of Notch signaling is the gamma-secretase protein complex and therefore, gamma-secretase inhibitors (GSIs)—
originally developed for Alzheimer’s disease—are now being evaluated in clinical trials for human malignancies. It is also
clear that Notch plays an important role in angiogenesis driven by Vascular Endothelial Growth Factor A (VEGF-A)—a
process instrumental for tumor growth and metastasis. The effect of GSIs on tumor vasculature has not been conclusively
determined. Here we report that Compound X (CX), a GSI previously reported to potently inhibit Notch signaling in vitro and
in vivo, promotes angiogenic sprouting in vitro and during developmental angiogenesis in mice. Furthermore, CX treatment
suppresses tumor growth in a mouse model of renal carcinoma, leads to the formation of abnormal vessels and an
increased tumor vascular density. Using a rabbit model of VEGF-A-driven angiogenesis in skeletal muscle, we demonstrate
that CX treatment promotes abnormal blood vessel growth characterized by vessel occlusion, disrupted blood flow, and
increased vascular leakage. Based on these findings, we propose a model for how GSIs and other Notch inhibitors disrupt
tumor blood vessel perfusion, which might be useful for understanding this new class of anti-cancer agents.
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Introduction
In the last decade dozens of new cancer drugs of the ‘‘targeted
therapy’’ class have been introduced. These drugs, for example
trastuzumab and imatinib, are based on efforts in basic research to
understand the cellular mechanisms underlying cancer develop-
ment. The majority of these drugs are designed to interfere with
growth promoting signaling pathways, hi-jacked by the tumor
cells. More recently, drugs affecting tumor growth indirectly,
through inhibition of VEGF-A-driven angiogenesis, have also
been introduced in the clinic [1,2]. Based on the success of the first
wave of targeted therapies, there is now a rapid development of
novel modulators of cell signaling pathways, DNA-repair,
proteolysis etcetera [3,4,5].
For more than a century, the Notch signaling pathway has
been known as a critical regulator of fundamental cell fate
decisions during development in Drosophila. Notch mainly exerts
its functions through lateral inhibition, a process by which a cell -
having acquired a certain phenotype - inhibits neighboring cells
to take the same path of differentiation. The result is two distinct
cell types, where both stem from cells with the same
developmental potential [6]. In vertebrates there are five known
Notch ligands (Delta-like 1, -3 and -4, Jagged 1 and -2), and four
Notch receptors (Notch1-4). As in Drosophila, the Notch system
controls development at multiple steps in almost all vertebrate
tissues. Both the ligands and receptors are cell surface bound and
require cell-cell interaction to trigger signaling. Furthermore,
ligand-receptor interaction leads to a series of proteolytic
cleavages, where the last step is mediated by the gamma-secretase
membrane protein complex, which minimally consists of the four
proteins Presenilin, Nicastrin, APH-1, and PEN-2. The series of
proteolytic cleavages leads to translocation of the Notch
intracellular domain (NICD) into the nucleus and initiation of
transcription [7]. Apart from being essential for normal
development, the Notch signaling system has been implicated
in human hereditary cardiovascular diseases and cancer [8,9].
For example, the Notch gene is translocated, mutated and over-
expressed leading to gain of function in a large number of
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renal, lung, pancreatic, ovarian, breast and prostate carcinoma
[10,11,12] and reviewed in [8].
Recently, our understanding of the role of Notch signaling in
angiogenesis in general, as well as in tumor angiogenesis, has
improved. During normal development, Delta-like 4 (Dll4) is
expressed by endothelial tip cells at the front of the angiogenic
sprout and signals via Notch1 to neighboring stalk cells trailing
behind, thereby suppressing differentiation of new tip cells and
sprouts. The disruption of this signal, by targeting Dll4 or Notch1
either genetically or pharmacologically, leads to increased
formation of endothelial tip cells, and in turn excessive angiogenic
sprouting [13,14,15,16,17], reviewed in [18]. In the tumor setting
the same mechanism operates so that Dll4 or Notch1 inhibition
drives extreme angiogenic sprouting, which generates non-
functional vasculature, in turn leading to inhibited tumor growth
[19,20,21,22,23], reviewed in [24].
Thus, there are multiple reasons for designing drugs disrupting
the Notch signaling pathway and various targeting approaches are
under way ranging from antibodies that selectively inhibit specific
Notch ligands or receptors, to low molecular weight compounds
disrupting the signaling of all four receptors [25]. The latter class
of compounds is based on inhibition of the gamma-secretase
protein complex, and is consequently termed gamma-secretase
inhibitors (GSIs). Apart from being essential for Notch signaling,
the gamma-secretase facilitates catalytic cleavage of several other
membrane proteins such as amyloid polypetide (APP), erbB-4,
CD44, E-cadherin etcetera [26]. The metabolic activity and
nutrient supply of the tumor cell might also be affected by GSI
treatment since mammalian target of rapamycin (mTOR) and the
glucose transporter Glut1 have been shown to be downstream of
Notch signaling [27,28]. The first GSIs in drug development were
aimed at treatment of Alzheimer’s disease based on the amyloid
hypothesis. However, there is now an increased interest in GSIs as
a potential treatment for hematological malignancies and cancer
since they have been shown to be efficacious in several tumor
models [29,30].
Despite thorough investigation of GSIs in tumor models,
surprisingly little effort has been directed at analyzing its effect
on tumor vessel morphology and functionality. We therefore
analyzed the effect of Compound X (CX), a GSI previously
reported to potently inhibit Notch signaling in vitro and in vivo [31].
Here we report that CX promotes VEGF-A-driven angiogenic
sprouting in vitro and during developmental angiogenesis. CX also
suppresses tumor growth in a renal carcinoma model, leads to the
formation of abnormal vessels and an increased tumor vascular
density. In a model of VEGF-A-driven angiogenesis in skeletal
muscle, we then demonstrate that CX promotes abnormal blood
vessel growth characterized by vessel occlusion, disrupted blood
flow, and increased vascular leakage. These findings might suggest
that GSIs act as anti-tumoral agents, not only via direct effects on
tumor growth, survival and differentiation, but also through action
on the tumor vasculature.
Results
Compound X promotes angiogenic sprouting both in
vitro and during mouse development
CX has previously been shown to potently inhibit gamma-
secretase activity and Notch signaling in vitro and in vivo [31]. To
test whether CX directly promotes angiogenic sprouting in vitro,w e
titrated CX in a cellular angiogenesis assay where clustered human
umbilical vein endothelial cells (HUVECs) form sprouts in a three-
dimensional collagen type I gel [32]. CX induced HUVEC
sprouting dose-dependently with an EC50 of 8.8 mM. (Figure 1).
To ascertain that GSI inhibitors affect angiogenesis similarly, we
also tested four other compounds; LY450.139, Sulfonamide
565763, WPE-III-31C and DAPT, pertaining to different classes
of GSI inhibitors. All compounds promoted angiogenic sprouting
dose-dependently (data not shown).
We and others have previously shown that genetic or
pharmacological inhibition of Notch signaling leads to increased
angiogenic sprouting in vivo during developmental angiogenesis of
the retina, reviewed in [18]. As expected, CX dose-dependently
increased the vascular density of the early postnatal retina at doses
between 5 and 20 mg/kg/day (Figure 1). Treatment with CX
between postnatal day (P) three and five led to increased vascular
density in the outermost two thirds of the retina, accompanied by
super numerous endothelial tip cells at the sprouting vascular front
in the periphery. In line with this, treatment with CX (10 mg/kg)
between P 3 and P 5 led to a 68% increase in the number of
endothelial filopodial protrusions at the vascular front, compared
to control (Figure 1). Thus, the pattern of vascular formation
after CX treatment was essentially morphologically indistinguish-
able from treatment with other GSIs such as DAPT [13]. The in
vitro and in vivo doses of CX, used to potently stimulate angiogenic
sprouting, were similar to the doses used to inhibit Notch signaling
in prior work by Searfoss et al. [31].
Compound X modulates the angiogenic response in a
model of renal cell carcinoma
To assess the effect of GSI treatment on tumor growth and
vessel formation in the tumor setting, we treated mice with CX
(10 mg/kg/day) in a model of renal cell carcinoma. Balb/C
RENCA cells were orthotopically implanted into syngenic mice at
day 0 and tumors were analyzed at day 21. Prior to animal
experiments we assessed the effect of CX on RENCA cell viability
at escalating doses in vitro, and found that it had no significant
effect even at the highest dose tested (10 mM), data not shown.
Hence, at the doses used in the study, CX affected angiogenic
sprouting but not cell viability. As seen previously in the RENCA
tumor model, vehicle-treated animals lost weight over time due to
their tumor burden and at day 20 the reduction was 5.5% of the
initial weight. CX-treated animals did not show a significant
weight reduction (Figure 2). At the end of the study, the primary
tumor volume and wet weight were both reduced after CX
treatment; 53% and 38% of control, respectively (Figure 2). The
Figure 1. CX dose-dependently promotes angiogenic sprouting and vessel growth in vitro and in vivo. (A) Dose-response curve for CX in
endothelial sprouting assay using HUVEC in type I collagen gels (EC50 value: 8.8 mM). Cumulative sprout length (CSL) was calculated from the ten
longest sprouts from ten HUVEC spheres. (B-E) Mouse retinas analyzed at day 5 after systemic treatment of mice, between postnatal day 3-4, with
vehicle, B or CX at 5 mg/kg, C, 10 mg/kg, D and 20 mg/kg, E. Endothelial cells were stained using Isolectin B4, white. There was a clear dose-
dependent increase in the vascular density after CX dosing. (F) There was a 68% increase in the number of filopodia protrusions per vessel length
when comparing CX-treated (10 mg/kg) retinas to vehicle (CX; 9.8 versus vehicle; 5.8 filopodia protrusions/100 mm, P-value=0.0041). (G-H) High-
magnification images of vehicle and CX-treated (10 mg/kg) retinas showing endothelial tip cells (white asterisks) with extensive filopodia protrusions,
isolectin B4-positive staining in black. Error bars represent standard deviation. The scale bars in B-E are 100 mm and in G-H 25 mm. **=P,0.01.
doi:10.1371/journal.pone.0018709.g001
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the number of CD31/PECAM1-positive structures per unit area,
was increased by 29% of control. The blood vessel morphology
was also altered. The vessel perimeter surrounding the CD31-
positive structures in the CX-treated group was increased by 33%
of control. However, the vessels were not dilated, but rather it
appeared as if several blood vessels were in the process of merging
into larger blood vessel structures (Figure 2). At the level of
endothelial cells, they appeared different in CX-treated tumors
compared to control. The endothelial surface was uneven and the
number of filopodia-like protrusions from endothelial cells were
more than doubled after CX treatment, compared to control
(Figure 2). The mural cell coverage of the tumor vasculature was
quantified as percentage of CD31-positive blood vessels that were
associated with a-smooth muscle actin (ASMA) positive cells. In
the vehicle treated group the ASMA-positive blood vessels were
few (16%) and most of them were only partially covered. The
mural cell coverage was reduced by 61% of control in the CX-
treated group (Figure 2). Interestingly, we also observed a higher
frequency of vessels filled with a CD31-positive content. In trying
to differentiate such vessels from the ones having merely been
tangentially sectioned, we quantified only large vessels with CD31-
positive content as being ‘‘occluded vessels’’, exemplified in
Figure 2. Occluded vessels were seen in proximity to areas
undergoing necrosis and were 2-fold more common in the CX-
treated tumors compared to vehicle control (Figure 2). Moreover,
the intraluminal occlusions were positive for the endothelial
markers CD31 and podocalyxin, as well as the nuclear stain DAPI,
suggesting that they are viable endothelial cells and not
membranous or matrix material (Figure S1).
Albeit we observed significant changes in microvascular density
and tumor size between vehicle and CX-treated animals, we failed
to quantify any differences in proliferation (BrdU-incorporation),
apoptosis (TUNEL and cleaved Caspase 3-staining), or area of
necrosis, data not shown.
Compound X disrupts VEGF-A induced neovascular
perfusion
To study the effect of CX on vascular morphogenesis and
functionality in a relevant, yet less complex milieu than that of a
tumor, we turned to the rabbit hind limb model. In this model,
adenoviral (Ad) VEGF-A165 gene transfer to the semimembranous
muscle led to vessel dilation and proliferation, not seen in skeletal
muscle transduced with a control gene, LacZ (Figure 3). Contrast
pulse sequence (CPS) ultrasound was used to determine the
perfusion in living animals [33]. Compared to the control leg,
VEGF-A165 gene transfer resulted in a more than 10-fold increase
of vascular perfusion (Figure 4). To determine the dose of CX to
be administered, several clinical chemistry markers were analyzed.
Even at low doses (1–2 mg/kg), there was a dose-dependent
increase in markers for liver stasis and toxicity including serum
total bilirubin (s-TB), serum alkaline phosphatase (s-ALP) and
serum alanin aminotransferase (s-ALT). In addition, we observed
an increase in the levels of serum creatinin, indicating kidney
damage (Table 1). Histological analysis of the liver, using CD31/
PECAM-1 staining, revealed dose-dependent severe dilation of the
sinusoids upon CX-treatment, as well as increased staining
intensity for CD31. Furthermore, intrahepatic bile ducts were
occluded by epithelial structures, a finding in line with the
increased s-ALP (Figure 5). Consequently, low doses of CX (1–
2 mg/kg/day) were chosen for further studies. In comparison to
AdVEGF-A-treated skeletal muscle, the combined administration
of CX and VEGF-A resulted in dose-dependent blood vessel
dilation and most notably an increased number of CD31/
PECAM1-positive structures filling the lumen of the vessels
(Table 2).
Staining for another endothelial marker, podocalyxin, also
identified the intraluminal structures as endothelial cells
(Figure 3). As the vast majority of the vessels follow the fibers
of the skeletal muscle, there is little risk of mistaking an occluded
vessel from a tangentially sectioned vessel. CX treatment also led
to a dose-dependent decrease in vascular perfusion, measured as a
reduced CPS signal. Doses of 1 or 2 mg/kg/day of CX reduced
CPS-signal by 48% and 66% of control, respectively (Figure 4).
In addition, blood vessel leakage was determined using the
modified Miles assay where extravasated Evans blue (intravenously
injected and subsequently bound to plasma proteins) was
quantified. Adenoviral gene transfer of VEGF-A led to a 35-fold
induction of Evans blue leakage. 2 mg/kg/day of CX treatment
resulted in a 76-fold increase in the leakage of the newly formed
vessels (Figure 4). Importantly, there were no differences in
permeability between vehicle treated and CX-treated muscles in
the absence of AdVEGF-A treatment.
Discussion
We noted a pronounced change in vascular architecture after
CX treatment in several model systems. During developmental
angiogenesis and in the tumor model, the endothelial cell surface
was rich in cytoplasmic protrusions and tip cell-like protrusions
Figure 2. CX treatment is anti-tumorigenic and promotes angiogenic sprouting in mouse renal cell carcinoma model. At day 0 twelve
mice were orthotopically inoculated with RENCA cells under the kidney capsule. (A) Mean animal weight plotted in relation to their initial weight.
There was a weight reduction in the control group, 1.0 g (a loss of 5.5% of initial weight), P=0.049 between day 1 and 20. There was no significant
weight reduction in the CX- treated cohort. At day 21 the study was terminated. (B) Tumor volume was reduced in the CX- treated group by 53% of
control, P=0.0055. (C) Tumor wet weight was reduced in the CX- treated group by 38% of controls, P=0.041. (D) Microvascular density (MVD) was
measured as the number of CD31 positive structures per area, and was increased by 29% of control after CX treatment, P=0.0080. (E) The number of
filopodia-like protrusions from the vessels profiles were increased by 130% in CX 10 mg/kg treated tumors compared to vehicle treated tumors (CX
10 mg/kg; 0.84 versus vehicle; 0.37 endothelial protrusions per vessel profile, P=0.017). (F) Vessel perimeter was calculated as the length surrounding
the CD31
+ blood vessel areas and there was a significant increase in the mean vessel perimeter in the CX-treated tumor as compared to control,
107 mm versus 85 mm, P,0.001. (G) The mural cell coverage was quantified as the fraction of CD31
+ vessels with associated ASMA
+ cells, and was 0.16
in the vehicle group and 0.06 in the CX-treated group, P=0.048. (H) The number of occluded vessels per area was increased 1.93-fold in CX- treated
tumors as compared to controls, P=0.010. (I and J) Representative tumor fields from control and CX-treated tumors stained with CD31. Black
structures are CD31 positive vessels in I-M. (K–L) A higher frequency of endothelial filopodia-like protrusions were observed after CX treatment
compared to control, black arrowheads point at filopodia-like protrusions. (M) Occluded vessels were identified as large vessel structures completely
filled with CD31-positive structures (arrowheads), clearly distinguished from small, and presumably, tangentially sectioned vessels. (N) Control tumors
stained for CD31, white structures. (O) CD31-stained CX-treated tumors form long continuous vessels structures that seem to arise from fusion of
several previously distinct vessels, e.g. center of image. (P) Example of CD31 (green) and ASMA (red) stained tumor section. Error bars represent
standard deviation. Compound X: CX. Scale bars are 100 mm, except K-L which are 25 mm. Significance level were indicated *= ,0.05, **=P,0.01.
***=P,0.001.
doi:10.1371/journal.pone.0018709.g002
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sprouting led to an increased number of vessels that eventually
coalesced into a sheet-like endothelial matt. CX treatment in the
RENCA tumor increased the number of blood vessel profiles and
the perimeter around the CD31-positive structures. These changes
are similar to what is seen after genetic loss or pharmacological
inhibition of Dll4 or Notch1. This leads to increased number of
endothelial tip cells and hypersprouting both during developmen-
tal- and tumor angiogenesis [13,14,15,16,17,19,21,23,34]. In
addition, we noted loss of ASMA-positive cells around the blood
vessels, which previously has been seen after endothelial specific
knockout of Jagged-1 or after Dll4 blockade during tumor
angiogenesis [22,35]. We hypothesize that the main effect of
CX-mediated inhibition of the gamma-secretase is blockade of
Notch signaling which leads to hypersprouting and the formation
of an immature vessel network that coalesce into larger vessel
structures. Furthermore, an interesting observation in our study
was the CD31- or Podocalyxin-positive structures that partially or
completely filled out the blood vessel lumen. These structures were
very notable in the rabbit hind limb model, where the capillaries
are cross-sectioned, but were also evident in the mouse tumor
model. Our use of two distinct markers for endothelial cells
strongly suggest that the cellular structures filling the vessel lumens
are of endothelial origin, but does not rule out contribution from
non-endothelial cells. Furthermore, others have reported vessel
occlusion following Dll4-inhibition in an in vitro model, where
HUVEC sprouting in fibrin gels led to the loss of lumen-like
structures, which were replaced by densely packed endothelial cells
[21]. Similarly it has been shown in the presenilin-1 knockout mice
that the brain capillaries are occluded by abnormally shaped
endothelial cells, which occasionally form multilayered stacks of
endothelial cells completely filling the vessel lumen [36]. We
speculate that the loss of Notch signaling leads to hyperprolifera-
tion of endothelial cells, which fail to organize properly and
thereby occlude the newly formed blood vessels. Moreover, we
observed that vascular leakage increased after GSI treatment. This
could be explained by the known inhibitory effect of Notch on
VEGF-A activity, since VEGF-A is known to potently induce
vascular leakage, reviewed in [37]. Furthermore, CX had no effect
on vascular leakage on its own further arguing that inhibition of
Notch signaling rather potentiate the effects of VEGF-A.
Alternatively, the abnormal vascular structures triggered by GSI
treatment could lead to reduced vascular integrity and increased
vascular leakage. Taken together, the abnormal vessel architecture
in combination with increased vascular leakage, could explain the
loss of vascular perfusion after CX treatment. Notably, we
administered 10 mg/kg/day to the mice without overt toxicity,
and the doses used in rabbits (1–2 mg/kg) were thus likely in the
low range in terms of modulating vessel growth. Therefore, had we
not observed symptoms of toxicity in rabbit model, higher dosing
would have been possible, with potentially even more dramatic
changes in vascular morphology.
In the tumor model, it is interesting to note that the occluded
vessels were most commonly observed in proximity of necrotic
areas. This could suggest that vessel occlusion led to loss of blood
vessel perfusion, which deprived the tumor of oxygen and
nutrients. However, we were not able to quantify any differences
in proliferation, apoptosis, or necrosis between CX and vehicle
treated tumors at the end of the study (day 21). Small additive
differences in the measured parameters could still lead to the end
result i.e. smaller tumors in the GSI treated group. Another
plausible explanation is a progressive tumor adaptation to the
treatment, in turn leading to immeasurable differences at day 21.
Early work by Paris and co-workers indicated that GSIs might
have an anti-angiogenic effect on endothelial cells in vitro and in
vivo, and inhibited tumor growth [38]. However, in contrast to that
study, but in line with the recent genetic and pharmacological
studies mentioned above, we found that CX promoted angiogenic
sprouting and vessel growth in vitro and during developmental
angiogenesis. The contrasting findings between our study and the
one by Paris and co-workers could be explained by the use of
different tumor models or different GSIs - where one of them does
not even inhibit Notch processing (JLK6) [39]. There were also
significant differences in administration, dosing of the GSIs, and
finally the fact that Paris et al. analyzed smaller sized tumors than
in the present study.
Figure 3. CX treatment leads to formation of abnormal
angiogenesis and vessel occlusion in model for VEGF-A driven
angiogenesis. (A–H) Cross section of rabbit skeletal muscle semi-
membranous muscle, hematoxylin staining in blue and endothelial
CD31/PECAM1 or Podocalyxin staining in brown, as indicated. (A) Thin-
walled capillaries are evenly interspersed in the AdLacZ-treated
(control) skeletal muscle. (B) 2 mg/kg CX treatment did not alter the
vascular morphology of the skeletal muscle capillaries. (C) Administra-
tion of VEGF-A165-isoform by adenoviral vector promotes an angiogenic
response resulting in dilation and proliferation of the existing vessels,
day six after gene transfer. (D–E) Addition of 1 or 2 mg/kg CX (D and E,
respectively) dose-dependently abrogates the normal VEGF-A response
and leads to the formation of PECAM1-positive structures occluding the
vessel lumen (arrowheads, F is a magnification of E). (G–H) The
endothelial marker, Podocalyxin, labeled the endothelial cells specifi-
cally in AdVEGF-A and CX-treated treated skeletal muscles, brown. (H)
Podocalyxin revealed the same cellular structures occluding the
vascular lumens after CX treatment as the CD31 staining. Scale bars
are 25 mm.
doi:10.1371/journal.pone.0018709.g003
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of the better-studied side effects is increased mucus production
leading to diarrhea, which stems from increased proliferation of
mucus producing Goblet cells, due to Notch inhibition [31]. In
addition, blockade of Notch results in altered lymphocyte
development including decreased number of mature B-cells [40].
Recently, it has also been shown that Dll4 or combined Notch1
and -2-inhibition can lead to development of vascular tumors and
hepatotoxicity [23,41]. Similarly, we found that CX treatment led
to severe hepatotoxicity in rabbits. This effect is likely triggered in
part by abnormal activation of liver endothelial cells as suggested
by Yan et al and Wu et al [23,41]. In addition, we observed
abnormal bile ducts and detected increased ALP-levels, indicative
of cholestasis. Interestingly, Notch signaling is important not only
for endothelial cells, but also for bile duct epithelial cells. For
example, Notch2, but not Notch1, has been shown to be
indispensable for normal perinatal and postnatal intrahepatic bile
duct development [42]. In addition, we found signs of renal
toxicity, which could be a GSI-class effect, alternatively toxicity
specific for CX. Despite these side effects, GSIs is still an
interesting class of drugs when compared to more selective agents
as therapeutic antibodies. GSIs have been shown to affect not only
tumor cell growth via Notch, but also other targets e.g. erbB-4,
mToR and Glut1 and thereby affecting other signaling pathways
important for tumor growth, nutritional status of the tumor and
possibly cancer stem cells [27,28]. Importantly, the gastrointestinal
side effects mediated by increased Goblet cell number have been
shown to be manageable using altered dosing regiments or
concomitant glucocorticoid treatment [30,43].
In conclusion we have shown that the GSI Compound X,
promotes angiogenic sprouting and neovascular formation during
development and tumor growth. Using a model of VEGF-A-
driven angiogenesis in the rabbit hind limb, we showed that CX
treatment resulted in vessel occlusion, reduced perfusion and
increased vascular leakage. We hypothesize that GSI treatment
leads to endothelial hyperproliferation and subsequent occlusion of
newly formed blood vessels, which leads to reduced vascular
perfusion. This vascular hypersprouting, in combination with
Figure 4. CX treatment leads to decreased perfusion and increased leakage after VEGF-A induced angiogenesis. Contrast pulse
sequence (CPS) ultrasound was used to measure vascular perfusion in the semimembranous muscle. The CPS-ratio between the VEGF-A adenovirus
gene transferred leg and the non-treated leg was compared. (A) VEGF-A induced a 10.3-fold increase in perfusion. There was a significant dose-
dependent reduction in the CPS ratio between VEGF-A transferred leg and the control leg when CX was systemically administered. The CPS ratio was
5.5 and 3.6 after administration of 1 and 2 mg/kg CX, respectively, ANOVA P=0.0040. (B) Evans blue was injected into the blood stream prior to
extraction of the muscle tissue. The signal between the VEGF-A treated muscle versus the non-treated leg was compared. There was a 35-fold
increase in Evans blue leakage after VEGF-A gene transfer, which was further increased by administration of CX. Doses of CX at 1 mg/kg or 2 mg/kg
resulted in a 40- or 76-fold increase in Evans blue leakage, respectively, ANOVA P=0.041. (C) Biopsies from the semimembranous muscle from either
AdVEGF-A165 treated or intact leg with the systemic treatment as indicated in the figure. The blue dye comes from extravasated Evans blue that is
trapped in the tissue. Compound X: CX. Error bars represent standard deviation. Significance level were indicated *=P,0.05, **=P,0.01.
***=P,0.001.
doi:10.1371/journal.pone.0018709.g004
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deprivation of the tumor.
VEGF-A driven angiogenesis is important for tumor oxygen
and nutrient supply. We have shown in models of VEGF-A-driven
angiogenesis that a GSI, inhibiting the Notch pathway, can
strongly affect vascular density, perfusion, and leakage. These
observations warrant further investigations of the role GSIs might
have in modulating tumor angiogenesis. Several compounds
targeting Notch signaling are under development for treatment
of a diverse array of malignancies [19,23,29,30,34,44]. Each of the
compounds has its pros and cons in terms of selectivity and efficacy
in blocking the Notch pathway. Further research will determine
which one of these compounds that ultimately can be used
effectively in the clinic.
Materials and Methods
Ethics statement
The developmental angiogenesis study was performed under the
license number: 354–04, granted by the Animal Ethics Commit-
tee, Go ¨teborg, Sweden.
The tumor study was performed using 8–10 weeks old female
BALB/c mice. Experimental protocols had been approved by the
Ethics Committee for Animal Experimentation according to the
United Kingdom Coordinating Committee on Cancer Research
Guidelines. The experimental protocol was registered by the
Regierungspra ¨sidium Freiburg (G-04/50).
The rabbit study was performed under the license number:
ISLH-2004-03492/Ym-23, study approved by University of
Kuopio Ethical Committee and license granted by County
Administrative Board.
Spheroid-based cellular angiogenesis assay
The Gamma-secretase inhibitor CX was synthesized as
described in [31]. The Spherogenex assay was performed as
described in [32]. Briefly, HUVECs were purchased from
PromoCell, Heidelberg, Germany, and cultured according to the
manufacture’s instructions. HUVECs clustered into spheroids in
cell culture media over night and dispensed in a 3-dimensional
collagen type I matrix. Spheroids were assayed for sprouting in the
presence of different concentration of CX for 24h and the ten
longest sprouts from 10 spheroids were summarized as cumulative
sprout length (CSL).
Immunohistochemistry of retinal vasculature
CX was dissolved in vehicle (10% ethanol and 90% corn oil)
and administered subcutaneously 5–20 mg/kg/day postnatal day
3 and 4. The eyes were isolated and retinas dissected on day 5.
Paraformaldehyde fixation and staining using isolectin B4 was
done as previously described [13].
RENCA tumor model
The study consisted of 2 groups containing 12 female BALB/c
mice each. At day 0, RENCA cells were orthotopically implanted
into the left kidney of all mice. Starting the following day (day 1)
animals in the treatment group received 10 mg/kg CX per os
(p.o.) once a day for the duration of 21 days. Animals of the
control group received vehicle (10% Ethanol, 90% corn oil) also
once a day p.o. starting day 1 until day 21.
At day 21 the study was terminated and a necropsy performed.
At necropsy, primary tumor weight and volume was determined.
For histological examination of the tumor vasculature, cryosec-
tions of primary tumor tissues (thickness = 5–10 mm) were taken
from all animals. For the visualization of the blood vessels,
immunohistochemical staining for CD 31 (1:500 PECAM-1 Cat.
553370, PharMingen, San Diego, CA) was performed, and vessels
were counted microscopically using a defined magnification
(x200), control treated (n=11) and CX-treated (n=9). For
fluorescent images, Alexa Fluor 488 donkey anti-rat IgG, (1:200,
A21208, Molecular Probes) was used. To stain for podocalyxin,
goat anti-podocalyxin (1:100, AF1556, R&D Systems, Minneap-
olis, MN) and donkey anti-goat IgG Alexa 488 (1:200, A-11055,
Table 1. Clinical chemistry parameters of VEGF-A and CX-treated rabbits.
Day 0 Day 6
Gene Transfer VEGF-A VEGF-A VEGF-A VEGF-A VEGF-A VEGF-A
Systemic treatment vehicle CX 1 mg/kg CX 2 mg/kg vehicle CX 1 mg/kg CX 2 mg/kg
S-ALP (U/L) 71±34 125624 105616 119620 50619 197637** 28867***
S-ALT (U/L) 48±13 37614 84622 70632 17672 3 2 667** 2826107**
S-TB (U/L) ,2.5 ,2.5 ,2.5 ,2.5 ,2.5 862.6** 3061.8***
S-CRP (mg/L) ,5 ,5 ,5 ,5 ,5 ,5 ,5
S-Creatinin (mM) 95±21 79610 7969.2 8869.2 89612 149626* 155626*
S-LD (U/L) 107±44 73621 69611 98616 127642 120619 140614
S-Na
+ (mM) 143±3 13266.5 13363.8 131613 13861.0 13660.81 141614
S-K
+ (mM) 4.2±0.3 4.660.24 3.760.19 4.260.14 4.360.14 4.260.35 3.660.57
Serum markers of toxicity and inflammation were assayed using blood samples from the rabbit at the beginning (day 0) and end of the study (day 6). Changes in serum
levels of the indicated markers were analyzed for statistically significant changes at day 6 between CX and vehicle-treated animals. In CX-treated rabbits there were
significant increases of alkaline phosphatase, alanine aminotransferase and total bilirubin indicating liver stasis and toxicity. There was also an increase in creatinin after
compound X treatment, suggesting renal toxicity.
Compound X: CX, S: serum, ALP: alkaline phosphatase, ALT: alanine aminotransferase, TB: total bilirubin, CRP: C-reactive protein, LD: Lactate dehydrogenase. Analyte
levels are given +/2 standard deviatio n. Reference values for rabbit are from Hewitt et al., and Ypsilantis et al.[48,49]. Significance level using students t-test.
*= ,0.05,
**=P,0.01.
***=P,0.001.
doi:10.1371/journal.pone.0018709.t001
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Muscle – Cy3 antibody, (1:100, C6198 Sigma, Saint Louis, MO,
USA) was used to visualize mural cells.
In addition, the proliferation index of the tumor tissue was
examined by BrdU labeling of the cryosections. For this purpose,
BrdU (500 mg/kg) was administered 12 h before sacrificing the
animals. Apoptotic index was determined using TUNEL (Cat. 12
156 792 910, Roche, Mannheim, Germany) and cleaved Caspase
3 stainings of tumor sections. Cleaved caspase-3 (1:500 #9661,
Cell Signaling Techn, Danvers, MA) and Alexa Fluor 555 donkey
anti-rabbit IgG (1:200 # A-31572, Molecular Probes, Eugene,
OR) were used. The determination of the necrotic areas within the
primary tumor was performed using the CD 31-stained tissue
samples. Necrotic areas were identified as areas in which no vessels
could be detected.
Rabbit hind-limb model
Gene transfer and GSI administration. New Zealand
White (NZW) rabbits (3.0–3.5 kg) were used for gene transfers.
Intramuscular gene transfers with adenoviral human VEGF-A
(n=9) and AdLacZ (n=1) were done into the hindlimb
semimembranosus muscle with method as previously described
[45,46]. Rabbits were anesthetized with medetomidine (Domitor
0,3 mg/kg, Orion, Finland) and ketamine (Ketalar 20 mg/kg,
Pfizer, Finland) and the total dose of 1610
11 virus particles in 1 ml
was divided to ten 100 ml injections. CX (1 mg/kg (n=3) or
2 mg/kg (n=3)) or vehicle (n=3) was administered by
subcutaneous injections once a day. Animals were euthanized six
days after gene transfer.
Ultrasound imaging. Skeletal muscle perfusion was
measured with Acuson Sequoia and Cadense Pulse Sequence
(Siemens) ultrasound imaging using 15L8 transducer of gene
transferred semimembranosus muscle and the contralateral intact
muscle, respectively[33]. Images were taken from transversal
sections after a single bolus (0.5 ml) of SonoVue contrast agent
(Bracco, The Netherlands). Measurements were performed six
days after gene transfer. Perfusion ratio between gene transduced
muscle and intact muscle was quantified with DataPro 2.13
software (Noesis) using the maximum signal intensities.
Modified Miles Assay. Modified Miles assay was used to
evaluate tissue edema [47]. Evans Blue dye (30 mg/kg) was
injected 30 min before euthanasia via ear vein. Animals were
perfusion-fixed with 1% paraformaldehyde in 0.05 M citrate
buffer (pH 3.5) via left ventricle after euthanasia. Muscles were
photographed, and samples were taken and weighted from both
gene transferred muscle and contralateral intact muscle. Evans
Blue dye was eluted in formamide and measured with
spectrophotometer of absorbance at 610 nm. Absorbance was
normalized to the sample weight and ratio between gene
transferred and intact muscle samples was calculated.
Histology of rabbit skeletal muscle. 7 mm thick paraffin
sections were stained with monoclonal antibody against CD31
(1:50, clone JC/70A, Dako, Glostrup, Denmark) and against
podocalyxin-like 1 (1:200, sc-23903, Santa Cruz Biotechnology,
Santa Cruz, CA). Signal detection was done with avidin-biotin-
horse radish peroxidase (HRP) system with diaminobenzidine
(DAB) (Vector Laboratories/LabVision). Microphotographs were
taken with an Olympus AX70 microscope (Olympus Optical,
Tokyo Japan) and with a ZEISS AxioImager.M2 (Zeiss, Jena,
Germany).
Quantification of occluded capillaries. A capillary was
considered occluded, and thus counted, if more than 50% of the
luminal area was filled with CD31 positive cells. Ten microscopy
fields (2006magnification) per animal were captured. Altogether
30 microscopy fields from each treatment group were used for the
quantification. Occluded capillaries were counted from the
proximity of the needle track in each muscle biopsy.
Figure 5. CX treatment alters liver morphology. (A–C) Liver
samples from rabbits were stained with CD31/PECAM1 (brown) and
counter-stained with hematoxylin (blue). (A) AdVEGF-A + vehicle, (B)
AdVEGF-A + 1 mg/kg CX and (C) AdVEGF-A + 2 mg/kg CX. Micropho-
tographs show representative liver portal triads. (B–C) Note the dose
dependent dilation of the liver sinusoids (arrowheads in C) as well as
the increased staining intensity of CD31 in CX-treated livers. The bile
ducts seemed occluded by intraluminal epithelial cells (asterisks in B
and C). A: Artery, V: Vein, B: bile duct. Scale bars are 100 mm.
doi:10.1371/journal.pone.0018709.g005
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Student’s t-test was performed for comparison of two groups
and ANOVA was performed for analysis of three groups. The t-
test was calculated as unpaired and two-tailed, except for the
analysis of ASMA-coated vessels that was calculated as one-sided.
This was based on the assumption that there would be a reduction
in the ASMA-positive cells in the treatment groups based on the
publication by Scehnet et al.[22]. Alpha values less than of 0.05
were regarded as significant. The Chi-square test was used when
analyzing the frequency of occluded vessels. The GraphPad Prism
software v. 5.01 was used for all statistical analysis.
Supporting Information
Figure S1 High resolution confocal images of vessels in the CX
treated tumors. RENCA tumors stained for Podocalyxin or CD31
(green), and DAPI (blue or white). (A) A vehicle treated vessel as
reference to B–D. (B) An example of a CX-treated tumor vessel
filled with podocalyxin-positive cells with blue DAPI-stained
nucleus, white asterisks. (C) Same image as B, where the green
channel was removed to more clearly see the nuclei, black asterisks
(DAPI in white). (D) A CX-treated tumor showing a partially
occluded lumen, filled with CD31-positive cells. Scale bars 25 mm.
(TIF)
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